Janssen claims FDA okay for would-be Tagrisso rival RybrevantJohnson & Johnson’s Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant Share XJanssen claims FDA okay for would-be Tagrisso rival Rybrevanthttps://pharmaphorum.com/news/janssen-claims-swift-fda-okay-for-precision-cancer-drug-rybrevant/
